Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Apollomics Inc Cl A (APLM)

Apollomics Inc Cl A (APLM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Apollomics Announces Settlement of Cayman Litigation GlobeNewswire - Wed Nov 19, 4:38PM CST

FOSTER CITY, Calif., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”) (Nasdaq: APLM) announced today entering into a settlement agreement (the “Settlement Agreement”...

APLM : 14.74 (+6.54%)
APLMW : 0.0185 (-2.12%)
Apollomics Announces Changes to its Board of Directors and Composition of Committees GlobeNewswire - Mon Nov 17, 10:00PM CST

FOSTER CITY, Calif., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a California-based late-stage clinical biopharmaceutical company, today...

APLM : 14.74 (+6.54%)
APLMW : 0.0185 (-2.12%)
Apollomics Announces Continued Listing on The Nasdaq Stock Market Following Hearing Cancellation GlobeNewswire - Wed Oct 15, 1:36PM CDT

FOSTER CITY, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a California based late-stage clinical biopharmaceutical company developing...

APLM : 14.74 (+6.54%)
APLMW : 0.0185 (-2.12%)
Nasdaq Resumes Trading in Apollomics Inc. GlobeNewswire - Tue Oct 14, 3:05PM CDT

NEW YORK, Oct. 14, 2025 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market ® (Nasdaq: NDAQ) announced that trading will resume in Apollomics Inc. Class A ordinary shares (Nasdaq: APLM) and warrants (Nasdaq:...

NDAQ : 90.29 (+2.23%)
APLM : 14.74 (+6.54%)
Apollomics, Inc. Company Operational Continuity Update GlobeNewswire - Mon Oct 13, 8:22PM CDT

FOSTER CITY, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), today announced the following company operational update. Apollomics...

APLM : 14.74 (+6.54%)
APLMW : 0.0185 (-2.12%)
Small Caps Shine Following Fed’s First Rate Cut in 9 Months wealthyventurecapitalist.com - Thu Sep 18, 1:38AM CDT

The Federal Reserve delivered its first rate cut in nine months, and small-cap stocks wasted no time celebrating. While the S&P 500 (SPX) dipped modestly and the Russell 3000 Index (RUA) closed near even,...

IPM : 1.8600 (+1.09%)
MNPR : 79.47 (+2.96%)
SPRC : 1.7700 (+3.51%)
BGM : 7.36 (-2.77%)
BLDP : 2.80 (+4.87%)
IWV : 388.88 (+0.15%)
SQFT : 3.96 (unch)
APLM : 14.74 (+6.54%)
GV : 1.4500 (-1.36%)
TVRD : 4.18 (+1.46%)
THH : 18.35 (+10.54%)
WFC : 90.21 (+0.96%)
Nasdaq Halts Apollomics Inc., Ltd. GlobeNewswire - Wed Sep 17, 4:48PM CDT

NEW YORK, Sept. 17, 2025 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market ® (Nasdaq: NDAQ) announced that trading was halted on September 17, 2025 in Apollomics Inc., Ltd. at 14:37:17 Eastern Time for additional...

NDAQ : 90.29 (+2.23%)
APLM : 14.74 (+6.54%)
APLMW : 0.0185 (-2.12%)
Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress GlobeNewswire - Thu Apr 3, 3:05PM CDT

APLM : 14.74 (+6.54%)
APLMW : 0.0185 (-2.12%)
Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib GlobeNewswire - Mon Mar 31, 7:00AM CDT

APLM : 14.74 (+6.54%)
APLMW : 0.0185 (-2.12%)
Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia GlobeNewswire - Fri Dec 20, 2024

APLM : 14.74 (+6.54%)
APLMW : 0.0185 (-2.12%)

Barchart Exclusives

Is This Dividend Stock a Buy for 2026 After Rising 265% in 2025? Barchart - Thu Dec 4, 6:30PM CST
Anglogold Ashanti shares have soared this year amid a spike in gold prices. While the shares might take a breather for now, it is a buy-on-the-dip candidate for 2026. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot